JP Morgan Chase
IDXG

JP Morgan Chase’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

JP Morgan Chase’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,572
Closed -$194K – 6061
2018
Q3 		$194K Buy
+12,572
New +$151K ﹤0.01% 4698
2017
Q2 		– Sell
-1,415
Closed -$37K – 5375
2017
Q1 		$37K Buy
+1,415
New +$50.6K ﹤0.01% 4605
2016
Q4 		– Hold
0
– – – 5232
2013
Q3 		– Sell
-154
Closed -$72K – 4494
2013
Q2 		$72K Buy
+154
New +$69.8K ﹤0.01% 4221

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

JP Morgan Chase's IDXG Position: Q4 2018 in Review

JP Morgan Chase sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2018, closing a stake of 12,572 shares — an estimated $194K sold.

JP Morgan Chase first reported a position in IDXG in Q2 2013 and held it in 3 quarters. The position peaked at $194K in Q3 2018. 20 funds tracked by Wall St. Rank hold IDXG as of Q4 2018.

  • JP Morgan Chase reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • JP Morgan Chase sold 12,572 Interpace Biosciences, Inc. Common Stock shares in Q4 2018, an estimated $194K.
  • JP Morgan Chase first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 3 quarters.
  • JP Morgan Chase's Interpace Biosciences, Inc. Common Stock position peaked at $194K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2018.

Based on JP Morgan Chase's 13F filing for Q4 2018, filed 11 Feb 2019.